Patents by Inventor John R. Cashman

John R. Cashman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE
    Publication number: 20110236931
    Abstract: Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.
    Type: Application
    Filed: April 14, 2009
    Publication date: September 29, 2011
    Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTE
    Inventors: John R. Cashman, Mary T. MacDonald
  • SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER
    Publication number: 20100298345
    Abstract: Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.
    Type: Application
    Filed: August 2, 2010
    Publication date: November 25, 2010
    Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTE
    Inventor: John R. Cashman
  • Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents
    Publication number: 20100190728
    Abstract: Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling.
    Type: Application
    Filed: May 31, 2005
    Publication date: July 29, 2010
    Applicant: Human Biomolecular Research Institute
    Inventors: John R. Cashman, James M. MacDougall
  • Diagnostic Methods and Genetic Markers for Alzheimer Disease
    Publication number: 20090263492
    Abstract: Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases.
    Type: Application
    Filed: March 19, 2009
    Publication date: October 22, 2009
    Inventors: John R. Cashman, Milan Fiala
  • INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-kappa B ACTIVATION
    Publication number: 20090247520
    Abstract: A method to identify selective inhibitors of antigen receptor-mediated NF-?B activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.
    Type: Application
    Filed: March 26, 2009
    Publication date: October 1, 2009
    Applicants: The Burnham Institute for Medical Research, The Human Biomolecular Research Institute
    Inventors: John C. REED, Ranxin SHI, John R. Cashman, Karl J. OKOLOTOWICZ, Daniel RE
  • Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
    Publication number: 20080188527
    Abstract: Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic acetylcholine receptor (nAChR). Also disclosed are pharmaceutical compositions comprising a compound of the invention, as well as methods of using the pharmaceutical compositions for treating or preventing a disease or disorder associated with nicotine-ingestion, or a disease or disorder amenable to treatment by selective modulation of nAChRs.
    Type: Application
    Filed: December 10, 2004
    Publication date: August 7, 2008
    Inventor: John R. Cashman
  • DNA sequence encoding flavin-containing monooxygenase
    Patent number: 6762052
    Abstract: Novel flavin-containing monooxygenase in substantially pure form is provided. Also disclosed are the cDNA and the reduced amino acid sequences, and fragments and derivatives thereof. The enzymes are useful in metabolism studies, in screening of compounds for biological or pharmacological activity, as well as serving as a bio-indicator of disease states or susceptibility to disease states.
    Type: Grant
    Filed: May 30, 2000
    Date of Patent: July 13, 2004
    Inventors: John R. Cashman, Noureddine Lomri
  • Naturally occurring compounds and their derivatives as cyclooxygenase 2 and/or 5-lipoxygenase inhibitors
    Patent number: 6365634
    Abstract: This invention discloses methods for treating inflammation by inhibiting the production of pro-inflammatory metabolites via the cyclooxygenase and/or lipoxygenase pathways, comprising administering 4-cumylphenol or salts or solvates thereof.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: April 2, 2002
    Assignee: C-P Technology Limited Partnership
    Inventors: Brett A. Russell, John D. Miller, John R. Cashman, Sirimevan A. Weerawarna